Michael Gendreau
Chief Medical Officer Dogwood Therapeutics
Seminars
Thursday 24th September 2026
Selective Sodium Channel Modulation to Deliver Meaningful Clinical Benefits in Chronic Chemotherapy-Induced Neuropathic Pain
1:00 pm
- A late-stage Phase 2 development program applying tetrodotoxin-based sodium channel modulation to treat chemotherapy-induced neuropathic pain
- Achieving durable pain reduction while minimizing CNS and systemic safety liabilities associated with chronic pain therapies
- Establishing clinical proof of concept for selective ion channel modulation in nonopioid pain management
Thursday 24th September 2026
Fireside Chat: Reflecting on Clinical Experience to Shape Next‑Generation Ion Channel Programs
2:00 pm
- Discussing how programs evolved in response to clinical data and operational realities
- Sharing insights gained through adaptation, iteration, and risk management during development
- Informing future discovery and development choices with experience-based perspective
